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ABSTRACT  
The article presents an innovative approach to a bactericidal drug design based on a cephem prodrug analogue 
– cefetamet pivoxil hydrochloride. The emergence of cefetamet pivoxil hydrochloride excipient systems 
(mannitol, hydroxypropyl methyl cellulose, pregelatinised starch, lactose monohydrate, magnesium stearate, 
polyvinylpyrrolidone) caused changes in the physicochemical properties of cefetamet pivoxil hydrochloride. 
They are significant for planning the development of an innovative pharmaceutical formulation. The biological 
activity profile of the prodrug was also modified. FTIR spectra were used to study interactions between cefetamet 
pivoxil hydrochloride and the excipients. The theoretical approach to the analysis of experimental spectra 
enabled precise indication of cefetamet pivoxil hydrochloride domains responsible for interaction with the 
excipients. The interactions between cefetamet pivoxil hydrochloride and the excipients resulted in some 
important physicochemical modifications: acceptor fluid-dependent changes in solubility and the dissolving rate 
as well as a decrease in the chemical stability of cefetamet pivoxil hydrochloride in the solid state, especially 
during thermolysis. The interactions between cefetamet pivoxil hydrochloride and the excipients also had 
biologically essential effects. There were changes in its permeability through artificial biological membranes 
simulating the gastrointestinal tract, which depended on the pH value of the acceptor solution. Cefetamet pivoxil 
hydrochloride combined with the excipient systems exhibited greater bactericidal potential against 
Staphylococcus aureus. Its bactericidal potential against Enterococcus faecalis, Pseudomonas aeruginosa and 
Proteus mirabilis doubled. The new approach provides an opportunity to develop treatment of resistant bacterial 
infections. It will enable synergy between the excipient and the pharmacological potential of an active 
pharmaceutical substance with modified physicochemical properties induced by the drug carrier. 
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INTRODUCTION 
β-lactam analogues are still a predominant class of antibiotics applied to patients in hospitals as well as 
outpatients. Oral administration of β-lactam antibiotics is often limited by the increasing resistance of bacterial 
strains caused by long use of these drugs, their low chemical stability, poor bioavailability and peculiar flavour 
[1-3]. 
The introduction of prodrugs of penam, cephem and carbapenem antibiotics allowed the use of analogues 
characterised by better solubility (e.g. ceftaroline fosamil), greater bioavailability (e.g. tedizolid phosphate) and 
less bitter taste (e.g. cefuroxime axetil) [4-6]. Regardless of the subgroup of these analogues, their prodrugs 
originated in consequence of esterification of the carboxyl group in particular systems of bicyclic rings in 
penicillins, cephalosporins and carbapenems. The acidic form of β-lactam antibiotic prodrugs is activated by 
intestinal esterases. According to the definition, a prodrug is not supposed to convert into its pharmacologically 
active form until enzymatic or metabolic activation occurs. Due to the low bioavailability of β-lactam antibiotics 
the labile β-lactam bond responsible for the bactericidal potency of antibiotics may cleave and violate the 
cleavage priority of the ester bond in consequence of uncontrolled conversion of the prodrug into its active 
form within the digestive system [7]. Earlier studies showed that β-lactam bonds in acidic analogues from all 
subgroups of β-lactam antibiotics tended to break under the influence of various physicochemical factors [8-
10]. Hydrogen and hydroxide ions as well as oxidising agents and temperature are the main determinants 
facilitating hydrolysis of labile ester and β-lactam bonds in solutions. Acid-base hydrolysis and oxidation of β-
lactam analogues are rapid processes responsible for the degradation of antibiotics in the acidic environment 
of the stomach. These processes are induced by bacterial β-lactamases. During preformulation and formulation 
work the degradation of antibiotics may be catalysed by excipients. In the solid phase, the degradation of β-
lactam analogues is induced by physicochemical factors such as humidity and temperature. The formation of 
degradation products different from those observed in acid-base hydrolysis shows that an increased rate of 
thermolysis at an elevated relative air humidity is an important limitation to the storage of β-lactam antibiotics. 
As outlined above, the presence of various degradation products and considerable lability of β-lactam antibiotics 
are vital safety aspects in antibiotic therapy. Specific products of β-lactam antibiotic degradation, such as 
haptens, cause the risk of anaphylactic shock [11]. 
Since labile oral active pharmaceutical ingredients (APIs) are required to be administered in the form of specified 
pharmaceutical formulations, it is necessary to examine the influence of excipients as agents modifying 
physicochemical properties crucial to pharmacotherapeutic safety and effectiveness (solubility, rate of release 
from drug-excipient systems, chemical stability and permeability) [12-15]. In view of this fact, it appears obvious 
that any modification affecting the physicochemical properties of labile prodrugs of β-lactam antibiotics requires 
detailed analysis.  
The aim of this study was to assess the effect of the excipients on the solubility, chemical stability, dissolution 
profiles, permeability through artificial biological membranes and bactericidal activity of a specific prodrug of 
β-lactam antibiotics. Cefetamet pivoxil hydrochloride was selected as a model substance. Cefetamet pivoxil 
hydrochloride is an oral third-generation cephalosporin antibiotic. Its active form is cefetamet, which is obtained 
in vivo as a result of hydrolysis of the ester bond. The compound exhibits excellent potency against penicillin-
sensitive Streptococcus pneumoniae, Streptococcus spp, Haemophilus influenzae, Moraxella catarrhalis, 
Escherichia coli, Proteus spp., Klebsiella spp. and Neisseria gonorrhoeae [16]. Cefetamet pivoxil hydrochloride is 
formulated only in tablets because of its intensive bitter taste and chemical instability in aqueous solutions. 
Binary systems of cefetamet pivoxil hydrochloride and selected excipients were prepared for the study. The first 
stage of the study involved assessment of the interaction between cefetamet pivoxil hydrochloride and the 
excipients in the aforementioned powder systems. Next, the influence of the excipients on the physicochemical 
properties and antibacterial activity of cefetamet pivoxil hydrochloride was investigated. These parameters 
provided reference for the powder systems of cefetamet pivoxil hydrochloride and the excipients. 
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2. Experiment 
2.1. Materials  
Cefetamet pivoxil hydrochloride ((6R,7R)-7-[[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-methoxyiminoacetyl] amino]-
3-methyl-8-oxo-5-thia-1-azabicyclo [4.2.0] oct-2-ene-2-carboxylic acid) was synthesised at the Department of 
Modified Antibiotics, Institute of Biotechnology, Warsaw, Poland. Cefetamet pivoxil hydrochloride is a white or 
almost white powder. All other chemicals and solvents of analytical grade were provided by Merck KGaA 
(Darmstadt, Germany). High quality pure water was prepared using an Exil SA 67120 purification system 
(Millipore, Billerica, MA). The following excipients were used to test the compatibility of cefetamet pivoxil 
hydrochloride: mannitol (Merck KGaA, Darmstadt, Germany), hydroxypropyl methyl cellulose (Sigma-Aldrich), 
starch (Colorcon, Harleysville, PA), lactose monohydrate (DFE Pharma, Goch, Germany), magnesium stearate (JRS 
Pharma, Rosenberg, Germany), and polyvinylpyrrolidone (Sigma-Aldrich). 
2.2. Preparation of mixtures of cefetamet pivoxil hydrochloride and excipients   
In order to investigate the apparent solubility, chemical stability, permeability through artificial biological 
membranes and bactericidal activity of a 1:1 mixture of cefetamet pivoxil hydrochloride with commonly used 
excipients (mannitol, hydroxypropyl methyl cellulose, pregelatinised starch, lactose monohydrate, magnesium 
stearate, polyvinylpyrrolidone), samples of cefetamet pivoxil hydrochloride were weighed into 5 mL vials.  
2.3. Characterisation of mixtures of cefetamet pivoxil hydrochloride and excipients 
Fourier transform infrared spectroscopy was used to identify interactions between cefetamet pivoxil 
hydrochloride and the excipients. Mixtures of cefetamet pivoxil hydrochloride with the selected excipients were 
prepared separately with IR grade KBr at a ratio of 1: 100. The corresponding pellets were prepared by applying 
pressure of 8 tonnes in a hydraulic press. Vibrational infrared spectra ranging from 400 to 4000 cm-1 were 
recorded with an FT-IR Bruker Equinox 55 spectrometer equipped with a Bruker Hyperion 1000 microscope. 
Changes in the positions and intensity of the experimental spectra of mixtures of cefetamet pivoxil hydrochloride 
and the excipients were identified by quantum chemical calculations based on DFT, which showed theoretical 
spectra of cefetamet pivoxil hydrochloride. The Gaussian 03 package was used for the calculations [17]. 
2.4. Changes in cefetamet pivoxil hydrochloride concentrations  
An HPLC Shimadzu Prominence-i LC-2030 C with additional Nano Quantity Analyte Detector (NQAD) QT-500 
was used for chromatographic separation. As the stationary phase a Kinetex C18 column (100 × 2.1 mm × 2.6 
µm) (Phenomenex, Torrance, CA) was used. The mobile phase composed of ammonium acetate (10 mmol L-1): 
methanol: acetonitrile (33:16:15 V/V/V). The flow rate of the mobile phase was 0.8 mL min-1. Separation was 
performed at 30oC. The wavelength of the UV detector was set at 254 nm. The evaporator temperature of the 
NQAD was set at 40oC. Clean dry air was used to nebulize the eluent at a pressure of 276 kPa and condensing 
liquid was water. Separation was performed at 30oC.  The HPLC-DAD method was validated for cefetamet pivoxil 
hydrochloride, including the selectivity of its degradation products formed by oxidation [18].  
2.5. Apparent solubility of mixtures of cefetamet pivoxil hydrochloride and excipients  
The apparent solubility of cefetamet pivoxil hydrochloride mixed with the excipients was measured with an 
Agilent 708-DS dissolution apparatus. A standard paddle method was used at 310 ± 0.5 K and a stirring speed 
of 50 rpm. Cefetamet pivoxil hydrochloride in its free form and physical mixtures of cefetamet pivoxil 
hydrochloride and the excipients weighed into gelatine capsules were placed in a spring in order to prevent 
flotation of the capsule on the surface of the liquid. The resulting samples were placed in 500 mL of media of 
simulated gastric fluids (pH 2.1) and phosphate buffer (pH 6.8) simulating the gastrointestinal environment. 
Dissolution samples (5.0 mL) were collected at specified time intervals. An equal volume of temperature-
equilibrated media was replaced and filtered through a 0.45 μm membrane filter. The HPLC-DAD method was 
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used to measure the concentrations of cefetamet pivoxil hydrochloride in acceptor solutions [18]. The values 
reported in this article are arithmetic means of six measurements. 
The model proposed by Moore and Flanner to compare dissolution profiles is based on two factor values, f1 and 
f2 [19-20]. The difference factor (f1) measures the percent error between two curves over all time points. f2 is a 
logarithmic transformation of the sum of squared error of differences between the test Tj and reference Rj system 
over all time points according to the formulas below: 
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where n is the sampling number, Rj and Tj are the percentage of the reference (cefetamet pivoxil hydrochloride) 
and test products (mixtures of cefetamet pivoxil hydrochloride and the excipients) dissolved at each time point 
j. Dissolution profiles are similar when the f1 value is close to 0 and f2 is close to 100 (FDA guidelines suggest 
that two profiles are similar if f2 is between 50 and 100). 
2.6. Chemical stability of mixtures of cefetamet pivoxil hydrochloride and excipients  
Mixtures of cefetamet pivoxil hydrochloride with the selected excipients (1:1) were prepared to test their 
compatibility. The mixtures were stored under stress conditions. The stability of the mixtures was investigated 
at increased RH (76.5%) at 348 K and in dry air (0% RH) at 363 K. At specified time intervals, determined by the 
rate of degradation, the vials were removed, cooled to room temperature and their contents were dissolved in 
distilled water and analysed with the HPLC-DAD method validated according to the ICH guideline [21]. 
2.7. Permeability of mixtures of cefetamet pivoxil hydrochloride and excipients  
Differences in the gastrointestinal permeability of cefetamet pivoxil hydrochloride in its free form and in mixtures 
were investigated with the PAMPA method (parallel artificial membrane permeability assay). The system 
consisted of a 96-well microfilter plate and a 96-well filter plate. It was divided into two chambers: a donor at 
the bottom and an acceptor at the top, separated by a 120-μm-thick microfilter disc coated with a 20% (w/v) 
dodecane solution of a lecithin mixture (Pion, Inc.). Aqueous solutions of cefetamet pivoxil hydrochloride and 
mixtures of cefetamet pivoxil hydrochloride and the excipients (0.2 mg/L) were prepared in a different 96-well 
filter plate and added to the donor compartments. The donor solution was adjusted to pH 2.73 and 6.20 (NaOH-
treated universal buffer). The plates were put together and incubated at 310K for 4h in a humidity-saturated 
atmosphere. After 4 hours of incubation the concentrations of cefetamet pivoxil hydrochloride in its free form 
and in mixtures with the excipients in the donor and acceptor compartments were measured with the HPLC-
DAD method. 
The apparent permeability coefficient (Papp) was calculated using the equation below: 
𝑃𝑎𝑝𝑝 =
−𝑙𝑛 (1 −
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where VD – donor volume, VA – acceptor volume, Cequilibrium – equilibrium concentration, CD – donor 
concentration, CA – acceptor concentration, S – membrane area, t – incubation time (seconds). Compounds of 
Papp < 1 x 10-6 cm/s are classified as those of low permeability, whereas those of Papp > 1 x 10-6 cm/s are classified 
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as high-permeability compounds [22]. The Papp of cefetamet pivoxil hydrochloride in its free and complexed 
forms was compared with the ANOVA test.  
2.8. Bactericidal activity of mixtures of cefetamet pivoxil hydrochloride and excipients 
The Minimal Inhibitory Concentration (MIC) was calculated for each reference strain from the American Type 
Culture Collection and for clinical isolates. The MICs for cefetamet pivoxil hydrochloride and its mixtures with 
the excipients (1:1) were assayed using serial dilutions on a Mueller–Hinton liquid medium (Merck, Germany). 
A microbial culture of standardised optical density was used in the experiment. The method followed the 
standards of the National Committee for Clinical Laboratory Standards (NCCLS) [23]. 
3. RESULTS 
The content of cefetamet pivoxil hydrochloride was analysed and checked for the presence of potential 
breakdown products in combination with the selected excipients (mannitol, hydroxypropyl methyl cellulose, 
pregelatinised starch, lactose monohydrate, magnesium stearate, polyvinylpyrrolidone). The chromatograms of 
the mixtures of cefetamet pivoxil hydrochloride and the excipients (1:1) did not reveal any peaks from 
breakdown products without chromophore structures (HPLC-DAD method) or non-chromophore ones (HPLC-
NQAD method). The research results excluded the chemical instability of cefetamet pivoxil hydrochloride in 
mixtures with the selected excipients at the moment of preparation. Due to the fact that the formation of more 
hydrophilic and soluble compounds was excluded at this stage it was possible to assess the influence of the 
excipients on the lipophilic form of the prodrug in further part of the research. 
The assessment of physical effects of the systems combining cefetamet pivoxil hydrochloride with the excipients 
was based on changes in FTIR spectra. The assessment of changes in the position of characteristic cefetamet 
pivoxil hydrochloride bands and their intensity was supported by the density functional theory. Therefore, first 
the bands which were significant to assessment of the identity of cefetamet pivoxil hydrochloride were identified 
(Fig. 2). Next, changes in the position and intensity of the characteristic bands were assessed when cefetamet 
pivoxil hydrochloride was added to mixtures with the selected excipients. The biggest changes in the cefetamet 
pivoxil hydrochloride spectra were found when it was combined with mannitol. There were much lesser changes 
when the prodrug was combined with polyvinylpyrrolidone (Fig. 1). The changes observed at 988 cm-1, which 
corresponded to the C-O stretching vibrations in the pivoxil group, and the changes observed at 988 cm-1 and 
1,038 cm-1, which corresponded to the C-N and N-O stretching vibrations in thiazole and cepem rings, let us 
indicate 2-methoxyiminoacetyl] amino] group and (2-amino-1,3-thiazol-4-yl) structure as cefetamet pivoxil 
hydrochloride domains engaged in interaction with the excipients. There were no changes observed in the 
spectra when cefetamet pivoxil hydrochloride was combined with starch, hydroxypropyl methyl cellulose and 
lactose. 
The second part of the research involved assessment of the influence of the selected excipients on the apparent 
solubility, chemical stability, permeability through artificial biological membranes and bactericidal activity of 
cefetamet pivoxil hydrochloride.  
The cefetamet pivoxil hydrochloride dissolving rate in the presence of the selected excipients (mannitol, 
hydroxypropylmethyl cellulose, pregelatinised starch, lactose monohydrate, magnesium stearate, 
polyvinylpyrrolidone) was measured in an acceptor fluid of pH 1.2 and pH 6.8. The systems under analysis did 
not differ in the shape of the dissolving rate curves as was expected, the cefetamet pivoxil hydrochloride 
dissolving rate varied according to the pH value of the acceptor fluid. When the pH 1.2 acceptor fluid was 
applied, cefetamet pivoxil hydrochloride dissolved faster both in its free form and in mixtures with the excipients. 
The dissolving rate did not improve significantly when cefetamet pivoxil hydrochloride was combined with the 
excipients. When the phosphate buffer (pH = 6.8) was used for cefetamet pivoxil hydrochloride with or without 
the excipients, the dissolving rates were slower (Fig. 2).  
As the ICH guidelines require that the compatibility of API-excipient systems should be assessed at higher 
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temperature and humidity, the next stage of the research consisted in assessing the influence of the excipients 
on the chemical degradation of cefetamet pivoxil hydrochloride at increased relative humidity (RH = 70%, T = 
343 K) and dry air (RH = 0, T = 393 K) [21]. Regardless of the stress conditions, the degradation of cefetamet 
pivoxil hydrochloride in its free as well as in complexed form was a pseudo-first-order reaction described by the 
equation below: 
 ln Ct = ln C0 – kobs t 
where Ct and C0 are the concentrations of cefetamet pivoxil hydrochloride, at time t = 0 and t, respectively and 
kobs is the rate constant of degradation reaction. The semi-logarithmic plots were linear and their slopes were 
equal to the rate constants of the reactions with the negative sign (-kobs). There were no peaks originating from 
an additional degradation product in the HPLC chromatograms of API-EXP systems. By contrast, there were 
peaks on the chromatogram of cefetamet pivoxil hydrochloride in its free form. The analysis of changes in the 
concentration of cefetamet pivoxil hydrochloride under both conditions of degradation showed that HPMC and 
PVP had the strongest influence catalysing the degradation of cefetamet pivoxil hydrochloride (Fig. 3). 
The comparison of the permeability of cefetamet pivoxil hydrochloride in its free form and in the excipient 
systems (the permeability coefficient values (Papp (A→B) and Papp (B→A)) through the artificial biological 
membrane system simulating the gastrointestinal tract showed that the diffusive permeability of API was 
reduced regardless of the excipients used. Interestingly, the pH value of the acceptor fluid was also particularly 
significant in this test. The greatest permeability of cefetamet pivoxil hydrochloride in its free form was noted at 
pH 2.73 (1.5661 x 10−5 cm/s). When it was combined with the selected excipients, the apparent permeability 
coefficients were significantly lower, i.e. PVP (0.1028 x 10−5 cm/s), HPMC system (0.07498 x 10−5 cm/s), mannitol 
system (0.0806 x 10−5 cm/s), lactose monohydrate system (0.0665 x 10−5 cm/s), magnesium stearate (0.0432 x 
10−5 cm/s). When the pH value of the acceptor fluid was 6.20, the combinations with two excipients (mannitol 
and PVP) were characterised by greater permeability, but the permeability of cefetamet pivoxil hydrochloride in 
its free form was lower than in the pH 1.2 acceptor fluid (Fig 4). 
Ten mostly Gram-negative bacterial species, including reference strains and clinical isolates, were analysed 
microbiologically to determine the inhibitory concentration of cephalosporin – cefetamet pivoxil hydrochloride 
(control sample) in combination with the excipients (mannitol, hydroxypropyl methyl cellulose, pregelatinised 
starch, lactose monohydrate, magnesium stearate, polyvinylpyrrolidone). The lowest values of the active 
substance concentration inhibiting the growth of bacteria were noted for the following species: Proteus mirabilis 
(reference strain and clinical isolate MIC=1.0 mg/L), Klebsiella pneumoniae (reference strain MIC=0.25 mg/L) 
and Escherichia coli (reference strain and clinical isolate MIC=1.0 mg/L). Staphylococcus aureus, Pseudomonas 
aeruginosa, Salmonella enteritidis and Salmonella typhimurium were the most sensitive species to cefetamet 
pivoxil hydrochloride. The MIC value for these strains amounted to 125 or 250 mg/L. It is noteworthy that when 
the excipients were added, the MIC value changed in some cases. There was a difference between the group of 
compounds which could be a potential source of carbon for bacteria and those which microorganisms could 
partly metabolise or which could not be metabolised at all. When mannitol and lactose were applied, the MIC 
value increased for most of the strains. The only exceptions were the clinical isolates of the Klebsiella pneumoniae 
and Enterobacter aerogenes species as well as all the strains of the Salmonella genus. The MIC value for these 
microorganisms did not change in the variant where cefetamet pivoxil hydrochloride was combined with 
mannitol, as compared with the active substance on its own. When cefetamet pivoxil hydrochloride was 
combined with lactose, the MIC value increased for most of the strains (except those of the Salmonella genus), 
as compared with the active substance on its own. The MIC value decreased especially in the variants where 
cefetamet pivoxil hydrochloride was combined with polyvinylpyrrolidone or hydroxypropylmethyl cellulose. 
There were different MIC values observed for the following species: P. aeruginosa, E. coli (for reference strains 
and clinical isolates) and Enterobacter aerogenes (mostly for the clinical isolate). The biggest difference was 
observed for strains of the P. aeruginosa species. The MIC value of cefetamet pivoxil hydrochloride was 125 
mg/L. When cefetamet pivoxil hydrochloride was combined with hydroxypropyl methyl cellulose, the MIC value 
amounted to 32 mg/L (Table 1).  
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4. Discussion 
The increasing bacterial resistance to a large number of different groups of antibiotics, including β-lactam 
antibiotics, is a serious clinical problem nowadays [24]. The effectiveness of treatment of bacterial infections with 
β-lactam antibiotics is significantly limited by their considerable chemical instability and low bioavailability, 
which limits their capacity to achieve the necessary bactericidal concentration after oral administration in vivo 
[25-27]. Prodrugs for β-lactam antibiotics are used in an attempt to reduce these limitations. However, it is 
necessary to remember that increased lipophility of a β-lactam analogue will reduce its solubility, modify its 
bactericidal effect and bioavailability. What is more, the combination of β-lactam antibiotics with the excipients 
may cause chemical changes resulting from lability of ester bonds (ester (at C-2) and amid (at C-7) bicyclic ring 
system) and physical effects resulting in significant physicochemical changes for the prodrug profile of action 
and its safety [28-29]. Therefore, it is important to define the effect of excipients on selected prodrugs, especially 
those with several labile bonds. Due to this fact, the main focus of the first stage of our study was to assess the 
potential physical and chemical changes in combinations of cefetamet pivoxil hydrochloride with the selected 
excipients such as: mannitol, hydroxypropyl methyl cellulose, pregelatinised starch, lactose monohydrate, 
magnesium stearate, and polyvinylpyrrolidone. The exclusion of chemical instability of cefetamet pivoxil 
hydrochloride should be associated with the fact that there are no acid forms of this prodrug, which would be 
more hydrophilic, easier to dissolve and more bactericidal. The fact that cefetamet pivoxil hydrochloride 
exhibited adequate chemical stability when it was combined with the excipients let us assess the influence of 
the excipients on the lipophilic form of the prodrug. The following characteristics were analysed: changes in the 
dissolving rate, permeability through artificial biological membranes simulating the gastrointestinal tract and 
bactericidal activity. 
The FTIR assessment of physical interactions between the components of mixtures showed that two domains of 
cefetamet pivoxil hydrochloride were particularly engaged in interactions with the excipients, i.e. the 2-
methoxyiminoacetyl] amino] group and the (2-amino-1,3-thiazol-4-yl) structure. Both groups exhibited 
considerable lipophility. Their interaction with selected macrostructures caused changes in the solubility of the 
lipophilic ester API form and its permeability through biological membranes. When cefetamet pivoxil 
hydrochloride was combined with mannitol and PVP, there were changes in the position and intensity of their 
spectra.  
Differences in the dissolving rate of cefetamet pivoxil hydrochloride in acceptor fluids of different pH values may 
have been caused by different ionic forms of the prodrug and interactions with the excipients blocking the 
lipophilic group. It was reported that the maximum stability of cefetamet pivoxil hydrochloride was observed 
within the pH values ranging from 3 to 5 [30]. This observation suggests that when the pH value is acidic, 
cefetamet is relatively stable and more soluble. The in vitro hydrolysis of selected prodrugs in simulated gastric 
and intestinal fluids of different pH values showed that the prodrug was not hydrolysed in the stomach (pH 1.2.). 
When the pH value decreased, the prodrug ester started to degrade (about 10%) [31]. The degradation of the 
ester bond and formation of the hydrophilic form of cefetamet at pH 6.8 may slightly increase the prodrug 
solubility. However, under these conditions the ionic form of the prodrug will mostly become degraded, so the 
overall drug solubility will decrease. It is also necessary to note the fact that more noticeable changes in the 
dissolving rate profiles of individual combinations with the excipients at pH 6.8 may cause exchanges of ions.  
During six months of the experiment the HPLC-UV method was used to assess the stability and compatibility of 
cefetamet pivoxil hydrochloride and its binary mixtures at 70°C and 70% RH as well as uncontrolled RH. The 
response was linear within the range studied (R² = 0.9882). The HPLC-UV method used for the quantitation of 
cefetamet pivoxil hydrochloride can detect thermal degradation and chemical interactions with excipients. In 
our analysis of the catalytic influence of the excipients on cefetamet pivoxil hydrochloride degradation there 
were no additional peaks except those observed during the degradation of cefetamet pivoxil hydrochloride. The 
concentration of cefetamet pivoxil hydrochloride in binary systems was slightly more reduced than the 
concentration of cefetamet pivoxil hydrochloride in its free form. Similarly, to other β-lactam analogues, 
humidity and temperature were important factors affecting the degradation of cefetamet pivoxil hydrochloride 
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in isolation and in combination with the excipients [32-34]. There was no alteration in the peak area. This 
indicates that the excipients were sufficiently compatible for use in solid dispersion of cefetamet pivoxil 
hydrochloride. Cefetamet pivoxil hydrochloride was the most degraded (approximately 9.17%, Table I) when it 
was mixed with hydroxypropyl methyl cellulose. Hydroxypropyl methyl cellulose, a coating agent and rate-
controlling polymer for sustained release formulations, may react with the carbonyl (hydroxyl) group of 
cefetamet pivoxil hydrochloride and accelerate hydrolysis of the β-lactam combination [35]. There was a similar 
result when cefetamet pivoxil hydrochloride was combined with polyvinylpyrrolidone. This finding suggests that 
polyvinylpyrrolidone. catalysed the degradation of cefetamet pivoxil hydrochloride under the conditions of high 
humidity and temperature. Previous reports showed that polyvinylpyrrolidone was incompatible with several 
APIs due to the generation of hydrogen peroxide, which is reactive and can initiate radical chain reactions or 
react directly with APIs, inducing their degradation [36-37]. There have been numerous reports on the instability 
of the β-lactam ring in β-lactam antibiotics due to the presence of an oxidising factor [38-39].  
The study on the cefetamet pivoxil hydrochloride permeability through artificial biological membranes 
simulating the gastrointestinal tract showed that the pH value strongly influenced the dynamics of cefetamet 
pivoxil hydrochloride absorption and the permeability of excipients. However, it is necessary to remember that 
the results of this study concern only the assessment of changes in the permeability through artificial biological 
membranes based on passive diffusion [40]. There have been suggestions that some carrier-mediated transport 
systems underlie the absorption mechanisms of amphoteric β-lactam antibiotics [41]. For example, the transport 
characteristics of aminopenicillins (ampicillin and amoxicillin), aminocephalosporins (cephalexin, cephradine and 
cefadroxil) and cefazolin were compared with the characteristics of an actively transported substance (D-
glucose) and a passively transported substance (L-glucose) [42]. In view of the results of our study, we might 
suggest that at pH 6 the presence of excipients significantly increases the cefetamet pivoxil hydrochloride 
permeability based on passive diffusion. Interestingly, in the combinations where cefetamet pivoxil 
hydrochloride physically interacted with excipients (mannitol and polyvinylpyrrolidone) their influence on 
changes in permeability was the greatest. According to data presented in publications, cefetamet pivoxil exhibits 
significant positive food effect (40% vs 50%) after oral administration [43]. Hence, it is recommended that 
cefetamet pivoxil be taken with meals [44]. Therefore, our study might provide indirect evidence that selected 
excipients increase the absorption of cefetamet pivoxil hydrochloride. 
 As far as the microbial activity is concerned, in comparison with older cephalosporins, such as cefalexin or 
cefaclor, cefetamet pivoxil is an oral cephalosporin with enhanced affinity for the target penicillin-binding 
proteins 1 and 3 and increased stability to beta-lactamases [45]. In our study there were high MIC values of 
cefetamet pivoxil hydrochloride noted both for reference strains and clinical isolates. It may have been caused 
by the fact that these strains produced extended spectrum beta lactamases (ESBL), which inactivate penicillins, 
especially 1st-3rd generation cephalosporins [46]. AmpC cephalosporinases are another type of beta lactamase 
which are responsible for the resistance of the following bacterial genera: Acinetobacter, Pseudomonas, 
Enterobacter spp., Citrobacter spp. and Klebsiella [47]. The analysis of the combinations of cefetamet pivoxil 
hydrochloride with the excipients showed differences between the group of compounds which might be a 
potential source of carbon for bacteria and the compounds which could not be fully metabolised by 
microorganisms. Mannitol and lactose increased the MIC value in most of the strains under investigation. Clinical 
isolates of the Klebsiella pneumoniae and Enterobacter aerogenes species as well as all the strains of the 
Salmonella genus were exceptions. The MIC value in the variant combining cefetamet pivoxil hydrochloride with 
mannitol was the same as in the active substance on its own. When cefetamet pivoxil hydrochloride was 
combined with lactose, the MIC value increased in most of the strains under investigation (except bacteria of 
the Salmonella genus), as compared with the active substance on its own. We can suppose that the increase in 
the MIC value was caused by the fact that these species were capable of metabolising excipients. In 
consequence, the populations of these species increased. Apart from that, some compounds, such as 
disaccharides and alcohols, may protect microorganisms from the unfavourable environmental stress generated 
by the presence of an active substance. However, it is noteworthy the MIC value decreased for some species, 
especially in the variants where cefetamet pivoxil hydrochloride was combined with polyvinylpyrrolidone or 
hydroxypropyl methyl cellulose. There were different MIC values observed for the following species: P. 
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aeruginosa, E. coli (for reference strains and clinical isolates) and Enterobacter aerogenes (mostly for the clinical 
isolate). The biggest difference was observed for strains of the P. aeruginosa species. The MIC value of cefetamet 
pivoxil hydrochloride was 125 mg/L. When cefetamet pivoxil hydrochloride was combined with hydroxypropyl 
methyl cellulose, the MIC value amounted to 32 mg/L. The authors of the study suppose that both the semi-
synthetic cellulose derivative and the preparation composed of polyvinyl acetate, polyvinylpyrrolidone and 
stabilisers such as sodium lauryl sulphate and colloidal silicon dioxide may be toxic or they may inactivate and 
weaken microorganisms, thus making them more sensitive to the active substance. 
CONCLUSION 
The systems combining cefetamet pivoxil hydrochloride with excipients are examples where physicochemical 
and biological properties were modified to design modern oral forms and to search for a new approach so as 
to obtain effective antibiotic systems in the post-antibiotic era. According to the authors of the study, the 
modification of physicochemical and biological properties resulted in the following significant achievements: (i) 
the pH value of the acceptor fluid determined the influence of the excipients on the solubility of cefetamet 
pivoxil hydrochloride, (ii) the degradation of selected excipients had catalytic effect on the chemical stability of 
cefetamet pivoxil hydrochloride, (iii) there were pH-dependent changes in the cefetamet pivoxil hydrochloride 
absorption based on passive diffusion in combinations with selected excipients, (iv) there were changes in the 
bactericidal activity of cefetamet pivoxil hydrochloride in combinations with selected excipients. To sum up, the 
approach characterises an effective and viable bactericidal potential as well as physicochemical properties 
required for innovative dosage of pharmaceutical forms. In search for new chemotherapeutic solutions, this 
approach to the treatment of resistant clinical infections also has the essential advantage of safety in the 
administration of substances. 
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Table 1 Values of MIC for cefetamet pivoxil hydrochloride and its mixtures with excipients. 
 
 
 
Microorganism 
CP 
CP + 
HPMC 
CP + 
lactose 
CP + 
mannitol 
CP + 
PVP 
CP + 
starch 
mg/L 
1. Proteus mirabilis ATCC 12453 1 1 4 4 0.5↓ 4 
2. Proteus mirabilis clinical isolates 1 1 8 4 0.5↓ 8 
3. 
Klebsiella pneumoniae ATCC 
31488 
0.25 0.25 8 1 0.25 1 
4. 
Klebsiella pneumoniae clinical 
isolates 
4 2↓ 8 4 2↓ 1 
5. 
Enterobacter aerogenes ATCC 
13048 
2 2 16 4 1↓ 2 
6. 
Enterobacter aerogenes clinical 
isolates 
4 2↓ 32 4 1↓ 4 
7. 
Enterococcus faecalis ATTC 
29212 
2 2 32 4 2 1↓ 
8. 
Enterococcus faecalis clinical 
isolates 
4 4 32 16 4 1↓ 
9. Escherichia coli ATCC 25922 1 0.5↓ 32 4 0.25↓ 1 
10. Escherichia coli clinical isolates 1 0.5↓ 32 4 0.25↓ 1 
11. 
Staphylococcus aureus ATCC 
25923 
125 125 250 250 125 32↓ 
12. 
Staphylococcus aureus clinical 
isolates 
125 125 250 250 125 64↓ 
13. 
Acinetobacter baumanii ATCC 
19606 
8 8 16 16 8 8 
14. 
Acinetobacter baumanii clinical 
isolates 
16 16 32 32 16 16 
15. 
Pseudomonas aeruginosa ATCC 
27853 
125 32↓ 250 250 64↓ 250 
16. 
Pseudomonas aeruginosa clinical 
isolates 
125 32↓ 250 250 64↓ 250 
17. 
Salmonella enteritidis ATCC 
13076 
125 125 62↓ 125 125 125 
18. 
Salmonella enteritidis clinical 
isolates 
250 250 62↓ 250 250 250 
19. 
Salmonella typhimurium ATCC 
14028 
125 62↓ 62↓ 125 125 125 
20. 
Salmonella typhimurium clinical 
isolates 
250 62↓ 62↓ 250 250 250 
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Figure 1 Spectroscopic interactions of cefetamet pivoxil hydrochloride in mixtures with mannitol (A) and 
polyvinylpyrrolidone (B). 
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Figure 2 Plots of cefetamet pivoxil hydrochloride dissolution in pH 1.2 (A) and pH 6.8 (B). 
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Figure 3 Chemical stability of cefetamet pivoxil hydrochloride in mixtures with excipients. 
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Figure 4 Permeability of cefetamet pivoxil hydrochloride in mixtures with excipients. 
 
 
 
 
 
